Inhibikase raises $50M via ATM sale to RA Capital
Inhibikase sold 25 million shares to RA Capital Management for $50 million gross proceeds. The funds are intended to support the IMPROVE-PAH Phase 3 study through topline data.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day